Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioatla Inc BCAB

Healthcare Biotechnology
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL... see more

Recent & Breaking News (NDAQ:BCAB)

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

GlobeNewswire March 26, 2024

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

GlobeNewswire March 19, 2024

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 7, 2024

INVESTIGATION NOTICE: Kaskela Law LLC Announces Shareholder Investigation of BioAtla, Inc. (BCAB) and Encourages Investors to Contact the Firm

Newsfile January 29, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of BioAtla, Inc. (NASDAQ: BCAB) and Encourages Investors to Contact the Firm

Accesswire January 13, 2024

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 20, 2023

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

GlobeNewswire December 13, 2023

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

GlobeNewswire December 6, 2023

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

GlobeNewswire December 5, 2023

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire November 30, 2023

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

GlobeNewswire November 28, 2023

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

GlobeNewswire November 7, 2023

BioAtla to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 6, 2023

BioAtla's Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award

GlobeNewswire October 12, 2023

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

GlobeNewswire October 10, 2023

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

BioAtla to Participate in Upcoming Investor Conferences in August

GlobeNewswire August 3, 2023

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

GlobeNewswire August 1, 2023

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

GlobeNewswire July 25, 2023

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

GlobeNewswire June 26, 2023